Joint Clinical Trials Office
Evaluation Of Talazoparib, a PARP Inhibitor, In Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
Molecular Pathogenesis of Plasma Cell Disorder
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 11, 2024
REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Study Summary
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 29, 2024
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 26, 2024
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 21, 2024
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 8, 2024
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 7, 2024
A Phase II Trial of Tazemetostat Plus Mosunetuzumab In Untreated Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 7, 2024